NCT05549947 is a Phase 2 clinical trial of SHR1819 in Moderate to Severe Atopic Dermatitis, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd..

Who is sponsoring NCT05549947?

NCT05549947 is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05549947?

Interventions in NCT05549947: SHR1819, Placebo.

What condition does NCT05549947 study?

NCT05549947 studies Moderate to Severe Atopic Dermatitis.

Is NCT05549947 still recruiting?

NCT05549947 is currently completed. Last updated 23 January 2024.

Last reviewed 2024-01-23 · How we verify

NCT05549947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Completed Phase 2 Last updated 23 January 2024

What this trial tests

Phase 2 trial testing SHR1819 in Moderate to Severe Atopic Dermatitis in 158 participants. Completed in 23 November 2023.

Timeline

8 October 2022

Primary endpoint
15 September 2023

23 November 2023

Quick facts

Lead sponsor	Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	158
Start date	8 October 2022
Primary completion	15 September 2023
Estimated completion	23 November 2023
Sites	1 location across China

Drugs / interventions tested

SHR1819 — full drug profile →
Placebo

Conditions studied

Moderate to Severe Atopic Dermatitis — all drugs for Moderate to Severe Atopic Dermatitis →

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Moderate to Severe Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.
Gu C, Yin H, Yang B, Ji S, et al · · 2026 · PMID 42210243 · DOI 10.1186/s12916-026-04952-3

Verify or expand the search:

Other recruiting trials for Moderate to Severe Atopic Dermatitis

Currently open trials in the same condition.

NCT06723080 — Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
NCT06468956 — Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis · Phase 3 · active not recruiting
NCT06136741 — A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopi · Phase 2 · active not recruiting
NCT06099704 — Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis · active not recruiting

Other Shanghai Hengrui Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06877247 — A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism · Phase 1 · completed
NCT06649292 — SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M · Phase 3 · recruiting
NCT06654440 — A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy · Phase 2 · recruiting
NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting
NCT06605222 — A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05549947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Hengrui Pharmaceutical Co., Ltd.
Last refreshed: 23 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05549947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing